Loading clinical trials...
Loading clinical trials...
The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.
This is a 72 months long randomized clinical trial longitudinally evaluating beta-cell function, as well as glycemic control and inflammatory markers in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.
Age
25 - 65 years
Sex
ALL
Healthy Volunteers
No
University of Texas Southwestern
Dallas, Texas, United States
Start Date
November 1, 2003
Primary Completion Date
December 1, 2011
Completion Date
December 1, 2011
Last Updated
December 14, 2017
58
ACTUAL participants
Metformin
DRUG
Insulin
DRUG
Metfomin
DRUG
Pioglitazone
DRUG
glyburide
DRUG
Lead Sponsor
University of Texas Southwestern Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04943861